PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Platform technologies

IP strategy for platforms that generate whole pipelines of products.

Evolve is a specialist pharmaceutical and biotechnology IP firm. Our team includes scientific experts in chemistry, biochemistry and pharmaceutical science, and we have managed IP strategy for products at every stage of the pipeline, including on-market medicines.

Contact us

Our expertise FAQs Insights Contact us

Related technologies: Lipid nanoparticles | Antibodies | ADCs | In vivo CAR-T | Gene therapies

Platform IP strategy

Big pharma is increasingly buying platforms rather than single drugs. A platform company needs IP that protects the engine as well as the products it generates, and that can be licensed, partnered and sold on its own terms.

The new gold rush in pharma is for the “blockbuster platform”, the technology that can generate a whole pipeline of products. Platforms include drug discovery engines and AI, delivery technologies such as LNPs and viral vectors, antibody and TCE formats, and cell engineering approaches.

Platform IP and product IP

Platform IP and product IP do different jobs. Platform claims protect the engine and can be licensed across fields. Product claims protect each clinical candidate and drive its loss of exclusivity date. We help you keep them in separate, clearly defined families, so that each can be licensed, partnered or sold on its own terms. The two also interact: a product using someone else’s platform may be patentable but still need a licence.

What to patent and what to keep secret

Not every part of a platform should be patented. For AI drug discovery and other data-driven platforms, much of the value may lie in data, models and know-how that are better protected as trade secrets, while the products the platform generates need strong patents. We help you decide what to file, when, and what to keep confidential.

Broad claims and their limits

Platform claims are often broad, and broad claims are tested differently around the world. In the US, Seagen v Daiichi Sankyo shows how strictly written description and enablement are applied to platform inventions. The EPO is generally more accepting of broad claims, but focuses on the technical problem solved, and Japan, China and other offices apply their own standards. We draft platform applications with clear pointers to preferred embodiments and fallback positions for each market.

Licensing and partnering

Platform deals turn on field definitions, ownership of improvements, rights to products generated in a collaboration, and what happens to the IP when a partnership ends. We help you structure and negotiate these terms, and present the platform estate clearly to investors and acquirers. Read more about our due diligence work.

Fractional IP counsel

Our fractional IP counsel model places a named senior patent attorney inside your team as your head of IP, separating platform and product IP, managing licences and collaborations, and presenting the estate clearly to investors and partners.

Why fractional IP counsel for platform companies? Platform companies have to keep platform and product IP apart, manage collaborations and explain the estate to investors and acquirers. Our patent directors have done this in-house, so they bring the real-world industry experience that you only get working in-house, supported by our team and AI tools. A traditional IP firm rarely sees the business side, and a lone consultant cannot cover the drafting, diligence and deals that platform companies need. We bring both, with a global strategic approach.

Evolve AI

Albert, our validity and competitive intelligence agent, maps competitor platform portfolios at speed, and Cassandra supports diligence on platform deals. Our attorneys still make every judgement call. Read more about Evolve AI.

Back to pharmaceuticals

FAQs

Should we patent our platform or keep it secret?

Often a mix. Parts of a platform that can be reverse engineered or independently developed are usually worth patenting. Data, models and process know-how may be better protected as trade secrets. Read more: IP strategy for AI-assisted drug discovery

How do we separate platform and product IP?

Into separate, clearly defined patent families where possible, with platform claims to the technology and product claims to each candidate. Divisional and continuation strategy can help, but the support for each must be in the application as filed.

Can broad platform claims survive in the US?

Only with strong support. US courts apply written description and enablement strictly to broad platform claims, so specific embodiments and data matter. Read more: Seagen v Daiichi Sankyo

What do acquirers look for in a platform estate?

Whether the platform can generate more than one product, whether the company owns or securely licenses every component, how long protection runs, and whether it holds in all the key markets. Read more: The great consolidation

Platform Evolve Insights

Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.

Navigating the complex LNP IP landscape

  • 1st July 2026
It is difficult to find a field of patent law in pharma and biotech at the moment that is more complicated and fast-moving than the field of lipid nanoparticles (LNPs). IP strategy for LNPs involves sophisticated science, multiple and overlapping technology platforms, trade secret and ownership disputes and global patent cross-litigation.
Gold bar carrying turquoise cubes on slender stalks on dark blue, Evolve abstract article image.
Gold bar carrying turquoise cubes on slender stalks on dark blue, Evolve abstract article image.

Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo)

  • 14th December 2025
The recent decision of the US Court of Appeals for the Federal Circuit in Seagen v Daiichi Sankyo overruled the jury decision in the District Court to find an ADC linker platform patent invalid for both lack of written description and enablement. 
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

IP strategy for the universal cell therapy revolution

  • 27th August 2025
The cell therapy landscape is at a pivotal moment. There is considerable pressure within the industry to solve the manufacturing and logistical challenges that have defined the first generation of cell therapies.
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

The great consolidation: Big Pharma buys the advanced therapy technology, not just the drug

  • 8th August 2025
The latest cell and gene therapy industry trends reveal a shift in strategy towards platforms.
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Freedom to operate versus patentability in biotech: What the difference is and why it matters

  • 9th June 2025
Discover the critical difference between patentability and freedom to operate in biotech, and why true innovation is your best strategy for navigating the complex intellectual property landscape.
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

IP strategy for AI-assisted drug discovery

  • 29th April 2025
AI has been hailed as a potentially revolutionary tool for accelerating and enhancing the difficult and expensive process of drug discovery. Medicine perhaps represents the field in which AI has the most to offer humanity. However, the nascent field of AI-assisted drug design also highlights the need for IP strategy to be as forward-looking and…
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Insilico Medicine: Lessons in IP strategy from a front-runner in AI-drug discovery

  • 5th February 2025
This post is based on a previous article on IPKat. The intersection of AI and pharmaceutical development presents unprecedented opportunities but also raises complex legal questions. Recent developments and successes in AI-drug discovery highlight some of the key IP issues in AI-drug development. Companies are being forced to tackle these issues head-on as the IP…
View more Insights

Contact us

Tell us about your platform and what is coming up, whether that is a first filing, a partnership, a financing or a deal.

We are happy to have an informal conversation about your programme, with no obligation. You can read more about our team, and we also write a regular newsletter on pharma and biotech IP.

Contact us
Subscribe to the newsletter

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice